Supplementary protection certificates (SPCs) have taken a step closer to being implemented in China after the National People’s Congress completed a one-month public consultation period on draft amendments to the Chinese Patent Law. The proposed amendments form part of a broader move towards stronger intellectual property (IP) protection in China that also includes pharmaceutical data exclusivity.
Acting on a State Council resolution, China’s National Medical Products Administration (NMPA) proposed a general framework for patent linkage and...